Wesley H. Anderson

Alzheimer disease brain atrophy subtypes are associated with cognition and rate of decline

Shannon L. Risacher, Wesley H. Anderson, Arnaud Charil et al. · Neurology · 2017 · 164 citations · Full text

LY2456302 is a novel, potent, orally-bioavailable small molecule kappa-selective antagonist with activity in animal models predictive of efficacy in mood and addictive disorders

Linda M. Rorick‐Kehn, Jeffrey M. Witkin, Michael A. Statnick et al. · Neuropharmacology · 2013 · 148 citations

Psychoactive Drug, Psychiatry, Functional Selectivity +7

M1 and M2 Muscarinic Receptor Subtypes Regulate Antidepressant-Like Effects of the Rapidly Acting Antidepressant Scopolamine

Jeffrey M. Witkin, C. Overshiner, X. Li et al. · Journal of Pharmacology and Experimental Therapeutics · 2014 · 95 citations

Dogs Can Be Successfully Trained to Alert to Hypoglycemia Samples from Patients with Type 1 Diabetes

Dana S. Hardin, Wesley H. Anderson, Jennifer Cattet · Diabetes Therapy · 2015 · 60 citations · Full text

An Allosteric Potentiator of the Dopamine D1 Receptor Increases Locomotor Activity in Human D1 Knock-In Mice without Causing Stereotypy or Tachyphylaxis

Kjell Svensson, Beverly A. Heinz, John M. Schaus et al. · Journal of Pharmacology and Experimental Therapeutics · 2016 · 45 citations · Full text